• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

急性髓系白血病当前生存情况及新进展的观点

Perspectives on current survival and new developments in AML.

作者信息

Rowe Jacob M

机构信息

Department of Hematology, Rambam Health Care Campus, Shaare Zedek Medical Center, 12 Shmuel Bait St, Jerusalem, IL, 9103102, Israel.

出版信息

Best Pract Res Clin Haematol. 2021 Mar;34(1):101248. doi: 10.1016/j.beha.2021.101248. Epub 2021 Jan 31.

DOI:10.1016/j.beha.2021.101248
PMID:33762103
Abstract

The past three years have witnessed remarkable progress in acute myeloid leukemia (AML). The approval and development of targeted therapies and novel agents has improved outcomes for patients with traditionally poor survival rates. This review has summarized the survival impact of chemotherapy-based regimens in AML and described recent advances that will be of significance in the near future.

摘要

在过去三年中，急性髓系白血病（AML）领域取得了显著进展。靶向治疗和新型药物的获批与研发改善了生存率传统上较低的患者的治疗效果。本综述总结了AML中基于化疗的治疗方案对生存的影响，并描述了近期取得的进展，这些进展在不久的将来将具有重要意义。

相似文献

1
Perspectives on current survival and new developments in AML.急性髓系白血病当前生存情况及新进展的观点
Best Pract Res Clin Haematol. 2021 Mar;34(1):101248. doi: 10.1016/j.beha.2021.101248. Epub 2021 Jan 31.
2
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.新型药物和方案在急性髓系白血病中的应用：2022 年美国血液学会年会最新进展。
J Hematol Oncol. 2023 Mar 3;16(1):17. doi: 10.1186/s13045-023-01411-x.
3
Azacitidine in adult patients with acute myeloid leukemia.阿扎胞苷用于成年急性髓系白血病患者。
Crit Rev Oncol Hematol. 2017 Aug;116:159-177. doi: 10.1016/j.critrevonc.2017.05.010. Epub 2017 Jun 3.
4
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
5
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.CC-486（口服阿扎胞苷）维持治疗急性髓系白血病的随机、III期QUAZAR AML维持试验设计
Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19.
6
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.单中心儿科应用维奈托克联合阿扎胞苷治疗骨髓增生异常综合征和急性髓系白血病的经验。
Pediatr Blood Cancer. 2020 Oct;67(10):e28398. doi: 10.1002/pbc.28398. Epub 2020 Jul 31.
7
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.伴有阿扎胞苷的维奈托克治疗未经治疗的急性髓系白血病患者的真实世界经验。
Blood Adv. 2019 Oct 22;3(20):2911-2919. doi: 10.1182/bloodadvances.2019000243.
8
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.阿扎胞苷改善了伴有骨髓增生异常相关改变的老年急性髓系白血病患者的临床结局，优于常规治疗方案。
BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6.
9
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.缓解期接受口服阿扎胞苷治疗的急性髓系白血病患者不良反应的管理：来自 3 期随机 QUAZAR AML-001 试验的经验。
J Hematol Oncol. 2021 Aug 28;14(1):133. doi: 10.1186/s13045-021-01142-x.
10
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.低甲基化药物治疗后出现的继发性 AML：结局、预后因素和治疗选择。
Curr Hematol Malig Rep. 2021 Feb;16(1):97-111. doi: 10.1007/s11899-021-00608-6. Epub 2021 Feb 20.

引用本文的文献

1
Targeting PRDX1 impairs acute myeloid leukemic blasts and stem cells by disrupting redox homeostasis.靶向PRDX1通过破坏氧化还原稳态损害急性髓系白血病母细胞和干细胞。
Cell Death Dis. 2025 Aug 18;16(1):627. doi: 10.1038/s41419-025-07831-6.
2
STAB1 Promotes Acute Myeloid Leukemia Progression by Activating the IKK/NF-κB Pathway and Increasing M2 Macrophage Polarization.STAB1通过激活IKK/NF-κB通路并增加M2巨噬细胞极化促进急性髓系白血病进展。
Cancer Sci. 2025 Jun;116(6):1508-1521. doi: 10.1111/cas.70044. Epub 2025 Mar 13.
3
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.
识别急性髓系白血病成人患者低风险发热性中性粒细胞减少症入院的预测因素。
Blood Adv. 2024 Dec 24;8(24):6161-6170. doi: 10.1182/bloodadvances.2024014291.
4
Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.接受阿糖胞苷和伊达比星诱导治疗的急性髓系白血病患者出现皮疹的危险因素。
Cancer Diagn Progn. 2024 Sep 1;4(5):617-622. doi: 10.21873/cdp.10372. eCollection 2024 Sep-Oct.
5
In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia.基于计算机预测的靶向 IQGAP1-GRD 结构域的化合物选择性抑制人急性髓系白血病的生长。
Sci Rep. 2024 Jun 4;14(1):12868. doi: 10.1038/s41598-024-63392-2.
6
SIRT2 inhibitor SirReal2 enhances anti-tumor effects of PI3K/mTOR inhibitor VS-5584 on acute myeloid leukemia cells.SIRT2抑制剂SirReal2增强PI3K/mTOR抑制剂VS-5584对急性髓系白血病细胞的抗肿瘤作用。
Cancer Med. 2023 Sep;12(18):18901-18917. doi: 10.1002/cam4.6480. Epub 2023 Sep 1.
7
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system.纳米载体药物递送系统在克服癌症耐药性方面的最新进展。
Cancer Drug Resist. 2023 Jun 20;6(2):390-415. doi: 10.20517/cdr.2023.16. eCollection 2023.
8
The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.吉妥珠单抗奥佐米星在急性髓系白血病患者挽救治疗中的应用：一项单中心真实世界经验。
Medicina (Kaunas). 2023 Mar 2;59(3):498. doi: 10.3390/medicina59030498.
9
Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.用于接受阿糖胞苷和伊达比星诱导治疗急性髓系白血病患者的用药说明表的有用性。
In Vivo. 2023 Mar-Apr;37(2):924-932. doi: 10.21873/invivo.13164.
10
Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia.结合经验知识、计算机分子对接和 ADMET 分析，从苦木中鉴定治疗急性髓系白血病的植物化学物质。
PLoS One. 2022 Jul 27;17(7):e0270050. doi: 10.1371/journal.pone.0270050. eCollection 2022.